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Abstract Incidental reports suggest that antenatal treatment
of pyridoxine dependent seizures (PDS) may improve
neurodevelopmental outcome of affected patients. Two
families with PDS are reported, both with two affected
siblings. Antenatal treatment with pyridoxine was instituted
during the second pregnancy in each family (50 and 60 mg
daily from 3 and 10 weeks of gestation, respectively).
Perinatal characteristics and neurodevelopmental outcome
at 4 (Family A) and 12 (Family B) years of age were
compared between the untreated and treated child within
each family. Meconium-stained amniotic fluid was present
in both first pregnancies and abnormal foetal movements
were noticed in one. In the treated infants, pregnancy and
birth were uncomplicated. In family A, postnatal pyridoxine
supplementation prevented neonatal seizures. Both children
in family A were hypotonic and started walking after
2 years of age; both had white matter changes on MRI, and
the first child was treated for squint. IQ was 73 and 98 in
the antenatally untreated and treated child, respectively. The
second child in family B developed seizures on the seventh
day, because pyridoxine maintenance therapy had not been
instituted after birth. Seizures responded rapidly to pyri-
doxine supplementation. MRI showed large ventricles and a
mega cisterna magna. IQ was 80 and 106 in the antenatally
untreated and treated child respectively. Both children had
normal motor development. These results suggest that
antenatal pyridoxine supplementation may be effective in
preventing intrauterine seizures, decreasing the risk of
complicated birth and improving neurodevelopmental out-
come in PDS.
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Introduction
Pyridoxine-dependent seizures (PDS; MIM 266100) is a
rare autosomal recessive disorder with an estimated birth
incidence between one in 396,000 [7] and one in 783,000
[4]. PDS has been recognised for over 50 years since the
first report by Hunt et al. in 1954 [17]. The classic
presentation of PDS consists of neonatal seizures that are
intractable to conventional anti-epileptic drugs but ade-
quately respond to pyridoxine (vitamin B6) administration.
In retrospect, about 20% of mothers report abnormal foetal
movements highly suggestive of intrauterine seizures [16].
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Birth can be complicated, as a third of the children present
with asphyxia and/or suspected hypoxic-ischaemic enceph-
alopathy [4, 16]. Not only is PDS characterised by seizures
but also by encephalopathic symptoms such as agitation,
jitteriness, irritability, startle reactions and feeding problems
[16]. Reports on cerebral imaging have shown cerebral
haemorrhage, non-specific white matter abnormalities,
hydrocephalus, hypoplasia of the posterior part of the
corpus callosum, cerebellar hypoplasia and a megacisterna
magna [5, 15, 19, 33]. At older age, cortical atrophy with
ventricular dilation is sometimes observed in affected
patients [5, 15, 34].
Until recently, PDS was a clinical diagnosis based upon
effective seizure control by pyridoxine administration. In
2006, mutations in the ALDH7A1 gene were shown to be
present in the majority of patients with a clinical diagnosis
of PDS [20, 24, 29, 31]. ALDH7A1 encodes the enzyme α-
aminoadipic semialdehyde (α-AASA) dehydrogenase that
plays a role in the degradation of the amino acid lysine. α-
AASA dehydrogenase deficiency leads to increased levels
of α-AASA in urine and plasma [24], and α-AASA can,
therefore, be used as a biomarker for PDS [10] There are at
least two pathophysiological mechanisms that play a role in
PDS. First, semi-aldehydes easily bind to many different
molecules, and accumulation of α-AASA might, therefore,
have toxic effects on the (developing) central nervous
system. Second, α-AASA is non-enzymatically converted
to L-delta(1)-piperideine-6-carboxylate, which is a metabo-
lite that binds pyridoxal-5-phosphate (the active B6
vitamer) and as such leads to secondary pyridoxal-5-
phosphate deficiency [24].
Despite successful seizure control with pyridoxine
substitution, the majority of surviving PDS patients
shows some degree of cognitive impairment, particularly
concerning expressive language development. Only
around 20% of treated PDS patients are described as
having a normal development [14, 16]. Reports of a
possible relationship between treatment delay and cogni-
tive impairment have been inconsistent [6, 7]. Incidental
reports of antenatal treatment with pyridoxine in a second
pregnancy suggest that this approach may be effective in
controlling intrauterine seizures [8] and may improve
developmental outcome [8, 17, 18, 25, 28, 30, 32].
However, only eight cases of antenatal pyridoxine
supplementation have been described, and with limited
follow-up. Furthermore, treatment sometimes only coin-
cidentally aimed for multi-vitamin supplementation in
low doses and for a limited number of months. The
importance of long-term follow-up is illustrated by
reports of PDS patients showing an average develop-
ment initially, though not based on a formal assessment
but experiencing developmental delays at a later stage
[6, 22, 23].
We report two PDS families from the Dutch PDS cohort
with long-term follow-up after antenatal treatment in a
second pregnancy.
Methods and patients
Currently, the Dutch PDS cohort comprises 14 living
children (born 1991–2007), including three families with
two PDS patients each. In two of these families, the mother
used pyridoxine daily during the second pregnancy from
the first trimester onwards. Methodology and results of α-
AASA measurements and ALDH7A1 mutation analysis
have previously been reported [10, 31]. Table 1 presents
patient data on the clinical course, imaging and outcome.
Case reports
Family A, Child 1 A girl was born at term with meconium-
stained amniotic fluid and Apgar scores of 7 and 8 after 1 and
5 min, respectively. She developed clinical seizures within 1 h
after birth. Initially, seizures were temporarily controlled by
phenobarbitone and clonazepam. Pyridoxine 50 mg was
administered intravenously when seizures recurred on the
fourth day of life; after this, seizures ceased within 5 min.
Subsequently, the girl became hypotonic and needed respira-
tory support for 2 days. All anti-epileptic drugs were
discontinued after administration of pyridoxine, and no
maintenance therapy with pyridoxine was instituted. Seven
days after the initial administration of pyridoxine, generalised
seizures recurred. Again, seizures responded to parenteral
administration of pyridoxine. The girl was diagnosed with
probable PDS (patient 10 [7]) according to the clinical criteria
of Baxter [4], and maintenance monotherapy with pyridoxine
15 mg/kg/day was instituted. In retrospect, the mother
reported abnormal jerky foetal movements highly suggestive
of intrauterine seizures. MRI of the brain on the fifth day of
life showed multiple bilateral lesions in the white matter on
T2, corresponding with cerebral oedema. Diffusion-weighted
images showed in general an increased apparent diffusion
coefficient (ADC) with numerous focal lesions with a
decreased ADC, corresponding with a structural abnormal
cerebral white matter and recent cytotoxic lesions containing
increased extracellular water. At the age of 5 months, a
second MRI showed a thin corpus callosum and slight
asymmetric ventriculomegaly without clear white matter
abnormalities. At 3 years of age (in 2006), the diagnosis of
PDS was proven at the metabolic and DNA level (Table 1).
At the time of this report, the child is 5 years of age and
seizure-free on pyridoxine monotherapy. She is hypotonic
and has motor dyspraxia. In addition, she was treated for
squint and did not walk until the age of 2.75 years. Mental
development according to the Snijders-Oomen Nonverbal
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Intelligence Test (SON-R) [26] is below average, particularly
in expressive language skills (Table 1). For these reasons,
she currently attends a school for special education.
Family A, Child 2 During the second pregnancy of a son,
the mother used pyridoxine 50 mg/day from the third week
of gestation. Pregnancy and birth, as well as the neonatal
period, were uneventful. From the first day of life,
pyridoxine supplementation 50 mg/day was instituted
which was increased to 150 mg/day at 6 months of age.
In the first year of life, no seizures were noticed; at age
1 year, the child experienced a febrile convulsion twice. At
1.5 years of age (in 2006), PDS was proven at the
metabolic and DNA level (Table 1). At the age of 4 years,
he had a right-sided hemi status epilepticus during a febrile
period with diarrhoea, which was controlled after 200 mg
pyridoxine administered intravenously. MRI of the brain at
age 1.5 years showed bilateral white matter abnormalities
and a thin genu corpus callosum. He started walking at age
2.25 years. At the present age of 4 years, he is slightly
hypotonic. His mental development, assessed using the
SON-R, is average, although there is a delay in expressive
language skills, needing extra support. His MRI still shows
circumscript bilateral frontal white matter abnormalities.
The parents have no other children and have an average
social economic status.
Family B, Child 1 The first child in this family, a girl, was
born with meconium-stained amniotic fluid. She developed
seizures 2 h after birth. Pyridoxine 60 mg/day was started
after the 10th week of life when trials with several anti-
epileptic drugs had failed to control her seizures [36].
Ultrasound and CT scan of the brain showed no cerebral
abnormalities, except for a small haematoma of the
tentorium cerebelli. A trial of withdrawal was never
performed and at 12 years of age PDS was proven at the
metabolic and DNA level (Table 1). At the moment of this
report, the child is 14 years old, attends a regular school
and has a normal motor development. A recent MRI of her
brain showed no abnormalities.
Family B, Child 2 The mother used 60 mg pyridoxine daily
during her second pregnancy from the 10th week of gestation
onwards. Pregnancy and birth were uncomplicated. Errone-
ously no pyridoxine maintenance therapy was instituted after
birth. The boy developed seizures on the seventh day of life,
after which, treatment was started with 60 mg pyridoxine
daily. Consequently, seizures were controlled. At 10 years of
age, PDS was proven at the metabolic and DNA level
(Table 1). The boy is currently doing well and shows no
abnormalities on neurological examination; he attends a
regular school and has a normal motor development. MRI of
the brain at age 12 years showed slightly enlarged lateral
ventricles and some enlargement of the cisterna magna with
a normal corpus callosum. Table 1 presents data on the
mental development of these children using the WISC-III
[21]. The parents have no other children and have an average
social economic status.
Discussion
In this report on antenatal treatment in PDS, the first child
was regarded as the ‘natural’ control patient of the
antenatally treated second PDS patient in that same family.
Pyridoxine was well tolerated by the mother, and no
abnormal foetal movements were reported in the antenatally
treated PDS patients. Moreover, pregnancy, labour and birth
were uncomplicated after antenatal treatment with pyridox-
ine. These observations suggest that antenatal treatment of
PDS may be an effective treatment to prevent intrauterine
seizures and reduce birth-related complications [16].
Within each family, the same intelligence test was used
to compare the sibs. In family A, a non-verbal develop-
mental test (SON-R) was used because this test has sound
psychometric properties and is often used for children with
speech problems, as was the case for these children. In the
second family, the WISC-III was used, which measures
both verbal and non-verbal capacities and is often used to
determine intellectual capabilities of children attending
regular education. The antenatally treated children in both
families were shown to have better test results than their
first-born sibs. This suggests that antenatal pyridoxine
treatment may improve mental development, although
some degree of developmental delay remained in the
second child of family A. We were not able to compare
the outcomes of the affected children to healthy non-
affected siblings, since there were none for both families.
All four parents have attended regular education.
Interestingly, in family B, the first child developed
clinical seizures 2 h after birth, whereas the second child
developed clinical seizures on the 7th day of life. In
children with PDS who stop pyridoxine treatment, seizure
recurrence is usually reported within 5–7 days [6, 16],
suggesting a pyridoxine ‘storage’ sufficient to temporarily
prevent seizure occurrence in these patients. These obser-
vations further suggest that in the present study, the second
child was adequately treated antenatally and that the
pyridoxine dose prevented seizures shortly after birth.
Conversely, seizure occurrence on day7 could also reflect
the different effect of withdrawal in neonates in whom
seizure recurrence can be delayed by up to 6 weeks [6].
This observation might indicate what the optimum pyri-
doxine dose might be during pregnancy. Hyperemesis
gravidarum is treated with 50–100 mg pyridoxine a day,
300 Eur J Pediatr (2010) 169:297–303
which is well tolerated by both mother and foetus [6].
Others suggested a necessarily daily supplement of 2.5 to
10 mg pyridoxine in all pregnant women and have shown
that the pyridoxine state of the mother significantly affects
the foetus [3, 11]. In general, only long-term use of
pyridoxine in doses over 200–300 mg/day is thought to
lead to adverse effects, especially reversible sensory
neuropathy, in healthy adults [27]. Based on these obser-
vations, we suggest that a daily dose of 50 mg is safe for
the mother and may prevent foetal seizures, complications
at birth and early neonatal seizures in PDS patients.
In the present study, MRI of the brain showed
abnormalities in three of the four reported children,
including in the antenatally treated children. This observa-
tion is important and suggests that antenatal pyridoxine
treatment does not guarantee normal brain development and
that additional mechanisms (besides seizure-induced injury)
may be involved in PDS patients. These may include either
toxicity due to elevated levels of α-AASA or the lack of
metabolite(s) after the metabolic block, both of which may
cause neuronal damage or changes irrespective of pyridox-
ine treatment. In that case, interventions to prevent or treat
these metabolic changes in PDS patients should be
investigated in order to improve future outcome in this
group. The disappearance of the neonatal white matters
abnormalities seen in patient 1 (Family A) has been
interpreted by us as the result of seizure control.
This is one of the few reports focusing on antenatal
treatment of anticipated or possible PDS in a second child,
including long-term and case-controlled follow-up. Until
now, antenatal treatment of PDS has been reported in only
eight patients [8, 12, 17, 18, 25, 28, 30, 32], and two of
these reports (regarding a family that moved from France to
England) might overlap [25, 30]. The reports are not
uniform regarding the daily antenatal doses, the period of
antenatal treatment, the reason for treatment or the reported
(side)effects (Table 2). No complications at birth and no
neonatal seizures in the first week of life were reported for
any of the treated patients. Only four patients were formally
tested regarding development outcome, all of whom
showed some degree of developmental delay. In the
remaining four patients, developmental outcome was either
roughly described as ‘normal’ (n=3) or ‘delayed’ (n=1).
Only one report mentioned a control PDS sib who did not
receive antenatal pyridoxine treatment; this report conclud-
ed that antenatal treatment does not improve outcome,
although the antenatally treated children scored about 10 IQ
points higher than the PDS patient that did not receive
antenatal pyridoxine [30].
Because of the autosomal recessive nature of PDS, the
recurrence risk is 25% in consecutive pregnancies. The
metabolic and genetic defect of PDS has recently been
elucidated [24], which gives the opportunity for prenatal Ta
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diagnostic investigation. In selected families, prenatal
diagnosis and/or antenatal pyridoxine treatment can be
offered. Antenatal pyridoxine treatment should start as early
as possible in pregnancy and not be postponed until the
results of eventual prenatal diagnostic tests are available.
In both families, the affected children were homozygous
for the—common—c.[1195G>C] mutation, which has a
relatively high frequency in the Netherlands (15 of 20
alleles [31]) and has also been frequently identified by
others (12 of 36 alleles [29]; 11 of 30 alleles [9]). The
mutation leads to substitution of glutamate at position 399
by glutamine (Glu399Gln) and is predicted to have a
negative effect on the binding capacity of α-AASA
dehydrogenase to the required cofactor NAD+, resulting in
decreased enzyme activity [35].
Intrauterine treatment of a foetus that suffers from a
genetic metabolic disorder is rarely possible. Our report
shows the possible positive effects that can be reached, and
it aims to increase the awareness of clinicians regarding this
‘unusual’ treatment modality. Besides PDS, there are at
least three other autosomal recessively inherited metabolic
disorders that are good candidates for antenatal treatment.
In 3-phosphoglycerate-dehydrogenase deficiency (a disor-
der of serine biosynthesis), supplementation of L-serine has
been successful [13]. Vitamin B12-responsive methylma-
lonic aciduria can be treated by supplementation of the
mother with high doses of vitamin B12 [1]. Finally, another
defect of pyridoxine metabolism, namely pyridox(am)ine-
5′-phosphate oxidase, should (at least theoretically) be
treatable by supplementation of pyridoxal-5′-phosphate,
the active form of pyridoxine [2]. The current study is
limited by its retrospective nature and the small sample
size, which is due to the rare nature of PDS. However, all
previous reports on antenatal treatment are case reports, and
most do not describe control patients. Prospective studies
on the effects of antenatal treatment of PDS should be
performed.
We conclude that after a previous child with PDS, there
are strong arguments to supply mothers with pyridoxine
during subsequent pregnancies. Using this approach, foetal
and neonatal seizures and birth-related complications in
affected sibs may be prevented. Finally, our data suggest
that antenatal treatment may improve developmental out-
come in subsequent PDS patients compared to untreated
siblings.
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